Daiki Murata

6PUBLICATIONS
28CO-AUTHORS
Predictive and prognostic markersMolecular targetsImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto

|Sep 05, 2024
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.

Daiki Murata, Koichi Azuma, Kenta Murotani

|Sep 15, 2023
Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.

Daiki Murata, Koichi Azuma, Norikazu Matsuo

|Nov 15, 2022
Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.

Daiki Murata, Koichi Azuma, Goushi Matama

|Sep 08, 2022
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.

Daiki Murata, Koichi Azuma, Saeko Tokisawa

Pageof 1

Frequent Collaborators

4 joint publications

Koichi Azuma

3 joint publications

Takaaki Tokito

2 joint publications

Akira Nakao

2 joint publications

Tatsuki Ikoma